Aubrey Stoch

815 total citations
16 papers, 331 citations indexed

About

Aubrey Stoch is a scholar working on Pediatrics, Perinatology and Child Health, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Aubrey Stoch has authored 16 papers receiving a total of 331 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pediatrics, Perinatology and Child Health, 4 papers in Oncology and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Aubrey Stoch's work include Pharmacological Effects and Toxicity Studies (3 papers), Gastroesophageal reflux and treatments (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Aubrey Stoch is often cited by papers focused on Pharmacological Effects and Toxicity Studies (3 papers), Gastroesophageal reflux and treatments (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Aubrey Stoch collaborates with scholars based in United States, Germany and United Kingdom. Aubrey Stoch's co-authors include JA Wagner, Marc L. Reitman, Christopher R. Gibson, Xiaoyan Chu, Stefan Zajic, Raja Venkatasubramanian, Ying Ding, Raymond Evers, Kathryn Roupe and Jocelyn Yabut and has published in prestigious journals such as Diabetologia, American Journal of Physiology-Endocrinology and Metabolism and Clinical Pharmacology & Therapeutics.

In The Last Decade

Aubrey Stoch

15 papers receiving 321 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aubrey Stoch United States 8 95 76 68 63 57 16 331
Tamara Božina Croatia 12 65 0.7× 34 0.4× 75 1.1× 30 0.5× 74 1.3× 34 312
Aziz Laurent United States 12 58 0.6× 115 1.5× 40 0.6× 138 2.2× 36 0.6× 15 416
Maria C. Kjellsson Sweden 14 65 0.7× 105 1.4× 52 0.8× 54 0.9× 42 0.7× 54 556
Jessica Bo Li Lu United States 12 53 0.6× 21 0.3× 97 1.4× 35 0.6× 48 0.8× 30 321
Arvid Jungnik Germany 11 124 1.3× 214 2.8× 34 0.5× 104 1.7× 27 0.5× 14 424
Jacqueline Marti-Jaun Switzerland 10 92 1.0× 39 0.5× 198 2.9× 85 1.3× 41 0.7× 15 463
C. Davis United States 5 53 0.6× 53 0.7× 118 1.7× 27 0.4× 39 0.7× 7 319
Marcos Navares‐Gómez Spain 12 64 0.7× 34 0.4× 171 2.5× 49 0.8× 73 1.3× 35 361
Chadi Abbara France 12 82 0.9× 13 0.2× 41 0.6× 94 1.5× 44 0.8× 58 464
Anisha E. Mendonza United States 10 26 0.3× 84 1.1× 29 0.4× 77 1.2× 77 1.4× 20 320

Countries citing papers authored by Aubrey Stoch

Since Specialization
Citations

This map shows the geographic impact of Aubrey Stoch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aubrey Stoch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aubrey Stoch more than expected).

Fields of papers citing papers by Aubrey Stoch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aubrey Stoch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aubrey Stoch. The network helps show where Aubrey Stoch may publish in the future.

Co-authorship network of co-authors of Aubrey Stoch

This figure shows the co-authorship network connecting the top 25 collaborators of Aubrey Stoch. A scholar is included among the top collaborators of Aubrey Stoch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aubrey Stoch. Aubrey Stoch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Gupta, Pranav, Azher Hussain, Anthony Ford, et al.. (2022). Clinical Formulation Bridging of Gefapixant, a P2X3‐Receptor Antagonist, for the Treatment of Chronic Cough. Clinical Pharmacology in Drug Development. 11(9). 1054–1067. 5 indexed citations
3.
Lassman, Michael E., Derek L Chappell, Thomas McAvoy, et al.. (2020). Experimental Medicine Study to Measure Immune Checkpoint Receptors PD‐1 and GITR Turnover Rates In Vivo in Humans. Clinical Pharmacology & Therapeutics. 109(6). 1575–1582. 3 indexed citations
4.
Liu, Maggie, Akintunde Bello, Salima Darakjy, et al.. (2019). Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development. Clinical Pharmacology & Therapeutics. 107(3). 514–520. 4 indexed citations
5.
Rudd, Deanne Jackson, et al.. (2018). 551. MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel. Open Forum Infectious Diseases. 5(suppl_1). S205–S205. 2 indexed citations
6.
Matthews, Randolph P., Deanne Jackson Rudd, Kerry L. Fillgrove, et al.. (2018). 546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration. Open Forum Infectious Diseases. 5(suppl_1). S203–S203. 2 indexed citations
7.
Beysen, Carine, Marcella Ruddy, Aubrey Stoch, et al.. (2018). Dose-dependent quantitative effects of acute fructose administration on hepatic de novo lipogenesis in healthy humans. American Journal of Physiology-Endocrinology and Metabolism. 315(1). E126–E132. 21 indexed citations
8.
Lepeleire, Inge De, Randolph P. Matthews, Dirk Schürmann, et al.. (2017). O6 Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least 7 days. Journal of Virus Eradication. 3. 2–2.
9.
Simen, Arthur A., Cynthia Gargano, Jang‐Ho Cha, et al.. (2015). A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone. Therapeutic Advances in Drug Safety. 6(3). 86–97. 16 indexed citations
10.
Peng, Joanna, William S. Denney, Bret J. Musser, et al.. (2014). A Semi-mechanistic Model for the Effects of a Novel Glucagon Receptor Antagonist on Glucagon and the Interaction Between Glucose, Glucagon, and Insulin Applied to Adaptive Phase II Design. The AAPS Journal. 16(6). 1259–1270. 15 indexed citations
11.
Simen, Arthur A., Junshui Ma, Vladimir Svetnik, et al.. (2014). Efavirenz modulation of sleep spindles and sleep spectral profile. Journal of Sleep Research. 24(1). 66–73. 10 indexed citations
12.
Tatosian, Daniel, Ying Guo, Andrea Schaeffer, et al.. (2013). Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin. Diabetes Therapy. 4(2). 431–442. 38 indexed citations
13.
Reitman, Marc L., Xiaoyan Chu, Xiaoxin Cai, et al.. (2010). Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial Design. Clinical Pharmacology & Therapeutics. 89(2). 234–242. 133 indexed citations
14.
Amakye, Dereck D., Wen Dai, Cynthia J. Girman, et al.. (2009). The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development. Clinical Pharmacology & Therapeutics. 86(1). 32–43. 41 indexed citations
15.
16.
Lepeleire, Inge De, Carol Addy, Paul Rothenberg, et al.. (2007). Brain CB-1 receptor occupancy of taranabant in lean subjects using CB-1R PET. Diabetologia. 50. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tamara Božina Breakdown of academic impact, for papers by Aziz Laurent Breakdown of academic impact, for papers by Maria C. Kjellsson Breakdown of academic impact, for papers by Jessica Bo Li Lu Breakdown of academic impact, for papers by Arvid Jungnik Breakdown of academic impact, for papers by Jacqueline Marti-Jaun Breakdown of academic impact, for papers by C. Davis Breakdown of academic impact, for papers by Marcos Navares‐Gómez Breakdown of academic impact, for papers by Chadi Abbara Breakdown of academic impact, for papers by Anisha E. Mendonza
Rankless by CCL
2026